A new method to detect cancer using DNA from blood samples
A low-cost, multiplexed digital high resolution melt platform for DNA methylation-based detection and identification of cancers in liquid biopsies
This study is working on a new, affordable way to find cancer early by looking for special DNA patterns in blood samples, which could help improve treatment outcomes for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10922699 on NIH RePORTER |
What this research studies
This research focuses on developing a low-cost and highly sensitive platform for detecting cancer through the analysis of circulating cell-free DNA (cfDNA) found in blood samples. By utilizing a unique assay called DREAMing, the project aims to identify specific DNA methylation patterns associated with tumors, even in early stages of cancer. This approach seeks to improve early cancer detection, which is crucial for better patient outcomes. The methodology involves analyzing very low concentrations of tumor DNA amidst a larger background of healthy DNA, making it a promising advancement in cancer diagnostics.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for cancer or those with early-stage cancer who are undergoing routine blood tests.
Not a fit: Patients with advanced-stage cancers or those who do not have detectable levels of cfDNA in their blood may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate cancer detection, potentially saving lives by allowing for timely treatment.
How similar studies have performed: Previous research has shown promise in using cfDNA for cancer detection, indicating that this approach could be a significant advancement in the field.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Wang, Tza-Huei Jeff — Johns Hopkins University
- Study coordinator: Wang, Tza-Huei Jeff
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.